A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...
CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.
Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...
A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...
Hosted on MSN
CRISPR breakthroughs shaping next-gen medicine
From cancer-targeting enzymes to AI-designed editors, CRISPR technology is rapidly evolving into safer, more precise tools for research and therapy. Innovations like ThermoCas9, chromosome silencing ...
Hosted on MSN
CRISPR meets cancer: the next precision leap
From targeting stubborn tumor genes like PIK3CA to designing ultra-precise editors like ThermoCas9, CRISPR is reshaping the fight against cancer. Researchers are now engineering cells that resist drug ...
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
We'll know more about the company's medium-term prospects by the end of the year.
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results